iFuse Implant System® Minimally Invasive Arthrodesis (iMIA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01741025 |
Recruitment Status :
Completed
First Posted : December 4, 2012
Last Update Posted : October 3, 2017
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sacroiliac Joint Pain | Device: iFuse Implant System Other: Conservative Management | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 103 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Multicenter Randomized Controlled Post-market Clinical Follow-up Trial Comparing the Effectiveness and Safety of the iFuse Implant System® Versus Conservative Management for Patients With Chronic, Disabling SI Joint Pain. |
Study Start Date : | June 2013 |
Actual Primary Completion Date : | December 15, 2015 |
Actual Study Completion Date : | September 24, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: iFuse Implant System
Surgical placement of iFuse implants in the affected SI joint
|
Device: iFuse Implant System
Placement of iFuse implant system via surgery |
Active Comparator: conservative management
Medications, physical therapy, information
|
Other: Conservative Management
Medications for pain, physical therapy, cognitive behavour therapy |
- The change in lower back pain as rated by the study subject using a 0-100 visual analog scale (VAS) at 6 months after initiation of treatment [ Time Frame: 6 months ]
- Change from baseline in lower back pain (VAS) [ Time Frame: 1, 3, 12 and 24 months ]
- Change from baseline in leg pain (VAS [ Time Frame: 1, 3, 6, 12 and 24 months ]
- Change in disability due to back pain (ODI [ Time Frame: 3, 6, 12 and 24 months ]
- Change in quality of life (EQ-5D [ Time Frame: 3, 6, 12 and 24 months ]
- Change in ambulatory and work status [ Time Frame: 1, 3, 6, 12 and 24 months ]
- Change in depression score (Zung Depression Scale [ Time Frame: 3, 6, 12 and 24 months ]
- Change in objective functional test (ASLR [ Time Frame: 3, 6, 12 and 24 months ]
- Change in walking distance [ Time Frame: 3, 6, 12 and 24 months ]
- Patient satisfaction and self-rating of disease state [ Time Frame: 3, 6, 12 and 24 months ]
- Serious adverse events [ Time Frame: during 24 months ]
- Device breakage, loosening and migration [ Time Frame: 12 months ]
- Surgical re-interventions of target SI joint(s) [ Time Frame: over 24 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 21-70 at time of screening
- Patient has lower back pain for >6 months or >18 months for pregnancy induced lower back pain
- Diagnosis of the SI joint as the primary lower back pain generator based on ALL of the following: a. Patient has pain at or close to the posterior superior iliac spine (PSIS) with possible radiation into buttocks, posterior thigh or groin and can point with a single finger to the location of pain (Fortin Finger Test), and b. Patient has at least 3 of 5 physical examination maneuvers specific for SI joint pain, and c. Patient has improvement in lower back pain NRS of at least 50% of the pre injection NRS score after fluoroscopic controlled injection of local anesthetic into affected SI joint(s) (including previous documented test <6 months ago)
- Baseline Oswestry Disability Index (ODI) score of at least 30%
- Baseline lower back pain score of at least 50 on 0-100 point VAS
- Patient has signed study-specific informed consent form
- Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements
Exclusion Criteria:
- Severe lower back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture
- Sacroiliac pathology caused by auto-immune disease (e.g. ankylosing spondylitis) and/or neoplasia (e.g. benign or malignant tumor) and/or crystal arthropathy
- History of recent (<1 year) fracture of the pelvis with documented malunion, non-union of sacrum or ilium or any type of internal fixation of the pelvic ring.
- Spine surgery during the past 12 months.
- Previously diagnosed or suspected osteoporosis (defined as prior T-score <-2.5 or history of osteoporotic fracture)
- Documented osteomalacia or other metabolic bone disease
- Any condition or anatomy that makes treatment with the iFuse Implant System infeasible
- Known allergy to titanium or titanium alloys
- Use of medications known to have detrimental effects on bone quality and soft-tissue healing
- Prominent neurologic condition that would interfere with physical therapy
- Current systemic infection or local infection at the SI joint
- Currently pregnant or planning pregnancy in the next year
- Known or suspected drug or alcohol abuse
- Diagnosed psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation
- Patient is participating in an investigational study or has been involved in an investigational study within 3 months of surgery

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01741025
Belgium | |
OLV Ziekenhuis Aalst | |
Aalst, Belgium, 9300 | |
La Clinique de l'Espérance | |
Montegnée, Belgium, 4420 | |
Germany | |
Charité - Universitätsmedizin Berlin | |
Berlin, Germany, 12200 | |
Universitätsklinikum Bonn | |
Bonn, Germany, 53127 | |
Praxisgemeinschaft "Leben in Bewegung" | |
Hilden, Germany, 40721 | |
Italy | |
Istituto Ortopedico Rizzoli | |
Bologna, Italy, 40136 | |
Ospedale Civile Di Legnano | |
Legnano, Italy, 20025 | |
IRCCS Policlinico San Matteo | |
Pavia, Italy, 27100 | |
Sweden | |
Aleris Specialistvård Ängelholm, Ortopedkliniken | |
Ängelholm, Sweden, 26262 |
Study Director: | Daniel Cher | SI-BONE, Inc. |

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | SI-BONE, Inc. |
ClinicalTrials.gov Identifier: | NCT01741025 |
Other Study ID Numbers: |
300134 |
First Posted: | December 4, 2012 Key Record Dates |
Last Update Posted: | October 3, 2017 |
Last Verified: | September 2017 |
Arthralgia Joint Diseases Musculoskeletal Diseases Pain Neurologic Manifestations |